Clinical Significance and Study of CYP3A5 Gene Detection in the Treatment of Nephrotic Syndrome in Children with Tacrolimus

Clinical significance and study of CYP3A5 gene polymorphism in the treatment of children with nephrotic syndrome

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900022334

Enrollment

Unknown

Registered

2019-04-05

Start date

2019-05-01

Completion date

Unknown

Last updated

2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nephrotic syndrome in children

Interventions

Case series:Tacrolimus dose adjustment

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for nephrotic syndrome; 2. Kidney syndrome (hormone resistance, frequency recurrence, hormone dependence type) requires the use of Tamos children; 3. A child or family member who has signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Poor renal fuction; 2. It has been confirmed that nephrotic syndrome is caused by genetic mutations, and the guidelines do not recommend the use of tacrolimus; 3. Signed Denial of Participation in the Project

Design outcomes

Primary

Measure	Time frame
CYP3A5 gene polymorphism;Tacrolimus blood concentration;serum albumin;Proteinuria/24h;	—

Countries

China

Contacts

Public ContactLiu Xin

Wuhan Children's Hospital

liuxinqch@126.com+86 13545341553

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026